

PREPARE

Platform foR European Preparedness Against (Re-)emerging Epidemics



PREPARE is funded by the European Union under Grant Agreement 602525

PREPARE is a clinical research network established with support of the European Union funding running from 1 February 2014 to 31 January 2019.

The challenge of **PREPARE** is to build Europe's capacity for harmonised large-scale clinical research studies on infectious diseases (ID), prepared to rapidly respond to any severe ID outbreak and providing real-time evidence for clinical management of patients and for informing public health responses.

At the core of **PRACTICE** are large pan-European clinical networks of primary care, hospital care and intensive care, building on the established clinical networks of GRACE, ESICM, COMBACTE, CAPNETZ, PENTA and SERGAS

> **PREPARE** clinical research network

> > > 600 hospitals

PREPARE is established because current clinical research initiated and implemented in response to severe ID outbreaks is typically delayed, isolated and fragmented. Therefore it has relatively little to no impact on improving patient outcomes and developing highquality evidence to inform clinical management strategies in case of severe ID outbreaks. PREPARE's challenge is to address the underlying causes of this problem, creating a paradigm shift in clinical research response to severe ID outbreaks.

in 35 European countries

> 600 general practitioners in 20 European counties



In these clinical networks, three large scale clinical research studies will be implemented:

PRACTICE Study A: 5,200 patients (children and adults) across Europe.

Multi-centre standardised observational and natural history clinical data study in hospitalised and community patients with acute respiratory infection, severe illness caused by central nervous system infections, severe diarrhea, or hemorrhagic fever.


PRACTICE Study B: 4,800 patients (children and adults) in 20 European countries. Multi-centre double-blinded randomised placebo-controlled interventional

trial on influenza-like-illness in primary care.

PRACTICE Study C: 2,000-4,000 patients (adults) in about 100-200 ICUs, in 10-15 countries. Adaptive randomised controlled trial to improve survival in intensive care units (ICUs)-admitted patients with severe acute respiratory infection.

These 3 clinical studies are complemented by studies aimed at identifying and implementing solutions to key ethical, administrative, regulatory and logistical bottlenecks to rapid initiation of clinical research responses to severe ID outbreaks and studies aimed to map pan-European clinical management of severe IDs and develop harmonised clinical case definitions, guidelines and pre-approved protocols for large multi-site clinical studies in Europe.

PREPARE will establish five platforms - PRACTICE, PATHOS, PREDICT, CRISP and CREATE - that together shape PREPARE's framework for rapid, harmonized, large-scale and fit-for purpose clinical research in response to any severe ID outbreak.



CRISP: Clinical Research Information Sharing Platform

PATHOS is PREPARE's platform for patient-oriented studies aimed at identifying the relative contributions of host- and pathogen factors to development of severe diseases across different aetiologies, ages and clinical backgrounds.

PREDICT is **PREPAREs**' laboratory platform providing diagnostic capacity to support the clinical studies in PRACTICE, storing and distributing wellcharacterised strains and clinical specimens and developing and validating rapid diagnostics.

CRISP is PREPARE's clinical research information sharing platform for the rapid collection, controlling and reporting of the PRACTICE studies and for the exchange of information within and between the clinical networks.

CREATE is PREPARE's training and education platform, reaching out to the different stakeholders of PREPARE involved with the clinical research response to severe ID outbreaks with online and practical courses and

CREATE: Clinical Research Education And Training in Europe

workshops.

